NEW YORK (TheStreet) -- The evolution of diabetes treatment will continue to improve as the years go on. TheStreet's Jill Malandrino is with Nadav Kidron, CEO of Oramed Pharmaceuticals (ORMP - Get Report), to discuss the company's new treatment.Kidron said there are three stages in which patients with Type II diabetes act to treat it: changing their diet and lifestyle, taking medicine orally, and finally, using insulin pumps or injections. Oramed has created an ingestible insulin pill that patients would take in the second stage of their process. By administering the drug early enough, Kidron said, the patient's need to use insulin injections or pumps would be postponed. He added that oral administration is much better than injection. By performing the latter, the insulin is injected directly into the bloodstream, whereas an ingestible pill goes first to the liver, which regulates the secretion of insulin into the bloodstream. Kidron concluded that it's an exciting time, as the company is expected to complete a Phase II trial for the drug by the end of the year, and is also working on a similar project for Type I diabetes. -- Written by Bret Kenwell in Petoskey, Mich. Follow @BretKenwell
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Opinion
Snap Takes Steps in Right Direction, But It's Still Far From a Sure Bet
Snap Inc.'s first quarter results delivered on Tuesday were encouraging. But the social media company still has a long way to go before it can prove that an investment in the stock makes sense at current levels.
As Morgan Stanley Regains Its Footing, Pressure on Its Stock Should Subside
With the bar set low ahead of earnings day, Morgan Stanley's all-around beat will likely serve as encouragement for investors to set aside concerns that had started to mount in the latter part of 2018.
Goldman Sachs Is a Good Low-Stakes Bet as It Looks to Shake Things Up
With its transformation efforts yet to pick up speed and the stock reaching rock-bottom valuations, competent execution of Goldman Sachs' business reinvention plans could propel the stock well above current levels within the next 12 months.
Disney Is Clearly Taking the Long View -- and Thinking Big -- with Disney+
In addition to pricing its video streaming service aggressively, Disney is promising to spend heavily on original content and absorb losses over the next five years.
Picking Tech Stocks Requires More Discipline Following the Nasdaq's Rally
With tech multiples having risen across the board, it's worth paying close attention to both valuations and business trends when trying to pick winners.